Raymond James Financial’s MacroGenics MGNX Stock Holding History

Raymond James Financial’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,313	Closed	-$5.22K	–	6013
2025 Q2	$5.22K	Buy	+4,313	New	+$6.26K	﹤0.01%	6152

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial's MGNX Position: Q3 2025 in Review

Raymond James Financial sold out of MacroGenics (MGNX) in Q3 2025, closing a stake of 4,313 shares — an estimated $5.22K sold.

Raymond James Financial first reported a position in MGNX in Q2 2025 and held it in 1 quarter. The position peaked at $5.22K in Q2 2025. 104 funds tracked by Wall St. Rank hold MGNX as of Q3 2025.

Raymond James Financial reported no remaining MacroGenics position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 4,313 MacroGenics shares in Q3 2025, an estimated $5.22K.
Raymond James Financial first reported a position in MacroGenics in Q2 2025 and held it in 1 quarter.
Raymond James Financial's MacroGenics position peaked at $5.22K in Q2 2025.
104 funds tracked by Wall St. Rank held MacroGenics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.